第二类抗结核方案治疗患者的治疗结果:简短回顾

G. AngelineGrace
{"title":"第二类抗结核方案治疗患者的治疗结果:简短回顾","authors":"G. AngelineGrace","doi":"10.4172/2161-1068.1000257","DOIUrl":null,"url":null,"abstract":"Tuberculosis (TB) is one of the leading causes of morbidity and mortality, especially in developing and underdeveloped nations. To add to the burden, drug resistant TB is on the rise and India is handling the dual burden of drug sensitive TB and resistant TB. Previously treated TB cases when compared to the newly diagnosed, have poor treatment success rates and nearly seven times higher incidence of multi drug resistant TB. Proper management of patients treated with Category-II anti-tuberculous treatment (ATT) can result in decrease in emergence of drug resistant bacilli and interruption of disease transmission. Very few studies have reported the treatment outcomes of re-treatment cases and the associated factors in the literature. Favourable outcome rates are highly variable among the failure, relapse and default subgroups. There are many challenges faced by the treating physicians in diagnosis, treatment and follow-up of the re-treatment cases. This review describes the outcomes of patients treated with Category-II ATT and the challenges in managing the previously treated cases successfully. Relapse type of retreatment cases had better success rates compared to other subgroups.","PeriodicalId":74235,"journal":{"name":"Mycobacterial diseases : tuberculosis & leprosy","volume":"8 1","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Treatment Outcomes among Patients Treated With Category II Antituberculosis Regimen: Short Review\",\"authors\":\"G. AngelineGrace\",\"doi\":\"10.4172/2161-1068.1000257\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Tuberculosis (TB) is one of the leading causes of morbidity and mortality, especially in developing and underdeveloped nations. To add to the burden, drug resistant TB is on the rise and India is handling the dual burden of drug sensitive TB and resistant TB. Previously treated TB cases when compared to the newly diagnosed, have poor treatment success rates and nearly seven times higher incidence of multi drug resistant TB. Proper management of patients treated with Category-II anti-tuberculous treatment (ATT) can result in decrease in emergence of drug resistant bacilli and interruption of disease transmission. Very few studies have reported the treatment outcomes of re-treatment cases and the associated factors in the literature. Favourable outcome rates are highly variable among the failure, relapse and default subgroups. There are many challenges faced by the treating physicians in diagnosis, treatment and follow-up of the re-treatment cases. This review describes the outcomes of patients treated with Category-II ATT and the challenges in managing the previously treated cases successfully. Relapse type of retreatment cases had better success rates compared to other subgroups.\",\"PeriodicalId\":74235,\"journal\":{\"name\":\"Mycobacterial diseases : tuberculosis & leprosy\",\"volume\":\"8 1\",\"pages\":\"1-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mycobacterial diseases : tuberculosis & leprosy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2161-1068.1000257\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mycobacterial diseases : tuberculosis & leprosy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2161-1068.1000257","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

结核病是发病和死亡的主要原因之一,特别是在发展中国家和不发达国家。使负担更加沉重的是,耐药结核病呈上升趋势,印度正在处理药物敏感结核病和耐药结核病的双重负担。与新诊断的结核病病例相比,以前治疗过的结核病病例的治疗成功率较低,耐多药结核病的发病率高出近7倍。对接受第二类抗结核治疗的患者进行适当管理可减少耐药杆菌的出现并阻断疾病传播。文献中很少有研究报道再治疗病例的治疗结果及其相关因素。在失败、复发和默认亚组中,良好的转归率变化很大。治疗医师在再治疗病例的诊断、治疗和随访等方面面临着诸多挑战。这篇综述描述了ii类ATT患者治疗的结果以及成功管理先前治疗病例的挑战。复发型再治疗病例与其他亚组相比成功率更高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Treatment Outcomes among Patients Treated With Category II Antituberculosis Regimen: Short Review
Tuberculosis (TB) is one of the leading causes of morbidity and mortality, especially in developing and underdeveloped nations. To add to the burden, drug resistant TB is on the rise and India is handling the dual burden of drug sensitive TB and resistant TB. Previously treated TB cases when compared to the newly diagnosed, have poor treatment success rates and nearly seven times higher incidence of multi drug resistant TB. Proper management of patients treated with Category-II anti-tuberculous treatment (ATT) can result in decrease in emergence of drug resistant bacilli and interruption of disease transmission. Very few studies have reported the treatment outcomes of re-treatment cases and the associated factors in the literature. Favourable outcome rates are highly variable among the failure, relapse and default subgroups. There are many challenges faced by the treating physicians in diagnosis, treatment and follow-up of the re-treatment cases. This review describes the outcomes of patients treated with Category-II ATT and the challenges in managing the previously treated cases successfully. Relapse type of retreatment cases had better success rates compared to other subgroups.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信